Alterity Therapeutics Limited (ATHE) Research

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Market snapshot

Symbol
ATHE
Price
$4.88
Day change
-5.06%
Market cap
$130.5M
P/E ratio
-8.37x
52-week range
2.66-7
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

    Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its pivotal Phase 3 program for ATH434 in treating Multiple System Atrophy (MSA).

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Dyadic International, Inc. (DYAI)
  • Evaxion Biotech A/S (EVAX)
  • Generation Bio Co. (GBIO)
  • IGC Pharma, Inc. (IGC)
  • Liminatus Pharma, Inc. Class A Common Stock (LIMN)
  • MAIA Biotechnology, Inc. (MAIA)

Recent insider activity

  • Cunningham Ann Michelle — trade (0 shares) on 2026-04-17
  • Stamler David Allen — trade (0 shares) on 2026-04-15
  • Stamler David Allen — trade (0 shares) on 2026-04-15
  • Stamler David Allen — trade (290400000 shares) on 2026-04-15
  • Stamler David Allen — trade (40000200 shares) on 2026-04-15

Open Alterity Therapeutics Limited (ATHE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.